Experimental cell therapy targets deadly childhood brain cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Initial Screening * Radiologically confirmed DIPG or other diffuse intrinsic brain stem glioma (Grade III or IV). * Patient and/or parents/guardian willing to consent to biopsy for obtaining tumor material for confirmatory diagnosis and/or tumor RNA extraction and amplification. * Biopsy confirmation of any grade of glioma (for patients with classic DIPG on neuroimaging or at least grade III glioma in case of other diffuse intrinsic brain stem gliomas) * Karnofsky Performance Status (KPS) of \> 50% (KPS for \> 16 years of age) or Lansky performance Score (LPS) of ≥ 50 (LPS for ≤ 16 years of age) assessed within 2 weeks prior to registration; * Bone Marrow; * ANC (absolute neutrophil count) ≥ 1000/µl (unsupported) * Platelets ≥ 100,000/µl (unsupported) * Hemoglobin \> 8 g/dL (can be transfused) * Renal; * Serum creatinine ≤ upper limit of institutional normal * Hepatic; * Bilirubin ≤ 1.5 times upper limit of institutional normal for age * SGPT (ALT) ≤ 3 times upper limit of institutional normal for age * SGOT (AST) ≤ 3 times upper limit of institutional normal for age * Patients of childbearing or child-fathering potential must be willing to use medically acceptable forms of birth control while being treated on this study. * Signed informed consent according to institutional guidelines. Post Biopsy * Patients with post-surgical neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration; * Pathologic diagnosis of glioma on tumor biopsy. Exclusion Criteria: * Patients with severe dysphagia, obtundation, or tetraplegia (poor risks for anesthesia and biopsy procedure); * Absence of tumor on biopsy specimen; * Pregnant or need to breast feed during the study period (Negative serum pregnancy test required) * Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection; * Patients with significant renal, cardiac, pulmonary, hepatic or other organ dysfunction; * Severe or unstable concurrent medical conditions; * Patients who require corticosteroids above physiologic doses (\>4 mg/day dexamethasone) after chemoradiotherapy; * Patients scheduled to receive any other concurrent anticancer or investigational drug therapy; * Prior allergic reaction to TMZ, GM-CSF, or Td; * Patients who are unwilling or unable to receive treatment and undergo follow-up evaluations at University of Florida; * Patient and/or parent/guardian demonstrating an inability to comply with the study and/or follow-up procedures.